Abstract
In evolution two pathways emerged for the biosynthesis of pyrimidine and purine nucleotides. The de novo biosynthetic pathway assembles nucleotides from small building blocks. By contrast, the salvage pathways provide mechanisms to recycle nucleosides and bases from the dead cells of tissues and from the blood stream1. In some lower organisms only one of these pathways operates2. However, in mammalians both de novo and salvage pathways function in all tissues. It has been recognized in the past 10 years that the activities of salvage enzymes in each of the biosynthetic segments of metabolism are markedly higher than those of the rate-limiting enzymes of de novo biosynthesis1.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
G. Weber, Biochemical strategy of cancer cells and the design of chemotherapy: G. H. A. Clowes Lecture, Cancer Res. 43: 3466 (1983).
T. Aoki, Initial steps of de novo pyrimidine nucleotide biosynthesis in parasites and mammalian tissues: purification, regulation, adaptation, and evolution, Jpn. J. Parasitology 43: 1 (1994).
G. Weber, S. Ichikawa, M. Nagai, and Y. Natsumeda, Azidothymidine inhibition of thymidine kinase and synergistic cytotoxicity with methotrexate and 5-fluorouracil in rat hepatoma and human colon cancer cells, Cancer Commun. 2: 129 (1990).
G. Weber, M. Nagai, N. Prajda, H. Nakamura, T. Szekeres, and E. Olah, AZT: a biochemical response modifier of methotrexate and 5-fluorouracil cytotoxicity in human ovarian and pancreatic carcinoma cells, Cancer Commun. 3: 127 (1991).
M. Abonyi, N. Prajda, Y. Hata, H. Nakamura, and G. Weber, Methotrexate decreases thymidine kinase activity, Biochem. Biophys. Res. Commun. 187: 522 (1992).
G. Weber, and N. Prajda, Targeted and non-targeted actions of anti-cancer drugs, Advan. Enzyme Regul. 34: 71 (1994).
N. Prajda, Y. Natsumeda, T. Ikegami, M.A. Reardon, S. Szondy, Y. Hashimoto, J. Emrani, and G. Weber, Enzymic programs of rat bone marrow and the impact of acivicin and tiazofurin, Biochem. Pharmacol. 37: 875 (1988).
M.J. Osborn, M. Freeman, and F.M. Huennekens, Inhibition of dihydrofolate reductase by aminopterin and amethopterin, Proc. Soc. Exptl. Biol. Med. 97: 429 (1958).
K. Pillwein, H.N. Jayaram, and G. Weber, Effect of ischemia on nucleosides and bases in rat liver and hepatoma 3924A, Cancer Res. 47: 3092 (1987).
C.J. Allegra, Antifolates, in: “Cancer Chemotherapy: Principles and Practice,” B.A. Chabner and J.M. Collins, eds., J.B. Lippincott Co., Philadelphia (1972).
M.S. Lui, M.A. Faderan, J.J. Liepnieks, Y. Natsumeda, E. Olah, H.N. Jayaram, and G. Weber, Modulation of IMP dehydrogenase activity and guanylate metabolism by tiazofurin (2-ß-D-ribofuranosylthiazole-4-carboxamide), J. Biol. Chem. 259: 5078 (1984).
G. Weber, IMP dehydrogenase and GTP as targets in human leukemia treatment, Advan. Exptl Med Biol 309B: 287 (1991).
G. Tricot, H.N. Jayaram, G. Weber, and R. Hoffman, Tiazofurin: biological effects and clinical uses, Intl. J. Cell Cloning 8: 161 (1990).
D. Wright, A role for guanine ribonucleotides in the regulation of myeloid cell maturation, Blood 69: 334 (1987).
E. Olah, Y. Natsumeda, T. Ikegami, Z. Kote, M. Horanyi, J. Szelenyi, E. Paulik, T. Kremmer, S.R. Hollan, J. Sugar, and G. Weber, Induction of erythroid differentiation and modulation of gene expression by tiazofurin in K-562 cells produced by inhibitors of inosine 5’-phosphate dehydrogenase, Cancer Res. 46: 2314(1986).
G. Weber, M. Nagai, Y. Natsumeda, J.N. Eble, H.N. Jayaram, E. Paulik, W. Zhen, R. Hoffman, and G. Tricot, Tiazofurin down-regulates expression of c-Ki-ray oncogene in a leukemic patient, Cancer Commun. 3: 61 (1991).
N. Prajda, Y. Hata, M. Abonyi, R.L. Singhal, and G. Weber, Sequential impact of tiazofurin and ribavirin on enzymic program of the bone marrow, Cancer Res. 53: 5982 (1993).
R.L. Singhal, Y.A. Yeh, K.Y. Look, G.W. Sledge, Jr., and G. Weber, Coordinated increase in activities of the signal transduction enzymes PI kinase and PIP kinase in human cancer cells, Life Sci., accepted for publication (1994).
R.L. Singhal, N. Prajda, Y.A. Yeh, and G. Weber, 1-Phosphatidylinositol 4-phosphate 5-kinase (EC 2.7.1.68): A proliferation-and malignancy-linked signal transduction enzyme, Cancer Res. Nov. issue, 54: (1994).
M.T. Rizzo, and G. Weber, 1-Phosphatidylinositol 4-kinase (EC 2.7.1.67): An enzyme linked with proliferation and malignancy, Cancer Res. 54: 2611 (1994).
G. Weber, and M.A. Reardon, Regulation of carbamoyl-phosphate synthase II, Advan. Enzyme Regal 25: 65 (1986).
A.M. Billi, L. Cocco, A.M. Martelli, R.S. Gilmour, and G. Weber, Tiazofurin-induced changes in inositol lipid cycle in nuclei of Friend erythroleukemia cells, Biochem. Biophys. Res. Commun. 195: 8 (1993).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1995 Springer Science+Business Media New York
About this chapter
Cite this chapter
Weber, G., Prajda, N., Singhal, R.L. (1995). Antimetabolites Reduce the Activities of Enzymes with Short Half-Lives in Addition to Inhibiting their Specific Targets. In: Sahota, A., Taylor, M.W. (eds) Purine and Pyrimidine Metabolism in Man VIII. Advances in Experimental Medicine and Biology, vol 370. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-2584-4_33
Download citation
DOI: https://doi.org/10.1007/978-1-4615-2584-4_33
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-6105-3
Online ISBN: 978-1-4615-2584-4
eBook Packages: Springer Book Archive